Diacerein untuk Penatalaksanaan Osteoarthritis

Oleh :

dr.Eduward Thendiono, SpPD,FINASIM

Beberapa studi telah menunjukkan potensi diacerein untuk penatalaksanaan osteoarthritis. Osteoarthritis (OA) merupakan jenis arthritis yang paling sering ditemukan dan merupakan salah satu penyumbang utama dari disabilitas pada populasi geriatri di seluruh dunia.

Penatalaksanaan OA derajat ringan utamanya bersifat simptomatik dengan pemberian paracetamol atau analgesik obat antiinflamasi nonsteroid (OAINS) dan modifikasi gaya hidup. Namun, penggunaan paracetamol yang terus menerus berhubungan dengan risiko gangguan fungsi liver, sedangkan OAINS meningkatkan risiko perdarahan gastrointestinal dan kejadian merugikan kardiovaskuler. [1-3]

Selain itu, baik paracetamol maupun OAINS tidak mempengaruhi proses patologik pada OA. Berdasarkan hal tersebut, dikembangkanlah terapi lini kedua atau yang dikenal dengan symptomatic slow-acting drugs for OA (SYSADOA). Adapun obat yang termasuk golongan tersebut adalah glukosamin sulfat, glukosamin hidroklorida, asam hialuronat, kondroitin sulfat, dan diacerein. Efikasi glukosamin dan kondroitin untuk OA telah ditinjau dalam penelitian.[4-6]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol.2014;10(7):437–41. doi: 10.1038/nrrheum.2014.44
2. McAlindon TE et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil. 2014;22:363–88. doi: 10.1016/j.joca.2014.01.003
3. Bruyere O et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).Semin Arthritis Rheum. 2014;44(3):253–63. doi: 10.1016/j.semarthrit.2014.05.014
4. Panova E, Jones G. Benefit-Risk Assessment of Diacerein in the Treatment of Osteoarthritis. G. Drug Saf. 2015;38: 245. DOI: https:// doi.org/10.1007/s40264-015-0266-z
5. Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis. 2010;2(2):95–104. doi: 10.1177/1759720X09359104
6. Pavelka et al. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs Aging 2016;33:75–85. DOI 10.1007/s40266-016-0347-4
7. Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moca Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014;2:CD005117. DOI: https://doi.org /10.1002/ 14651858. CD005117.pub3
8. Bartels EM et al. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthr Cartil. 2010;18(3):289–96. doi: 10.1016/j.joca.2009.10.006
9. Kongtharvonskul J et al. Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. European Journal of Medical Research (2015) 20:24. DOI 10.1186/s40001-015-0115-7
10. Pelletier JP, Raynauld JP, Dorais M, Bessette L, Dokoupilova E, Morin F, Pavelka K, Paiement P, Martel-Pelletier J; DISSCO Trial Investigator Group. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. Rheumatology (Oxford). 2020 Dec 1;59(12):3858-3868.
11. Honvo G, Reginster JY, Rabenda V, Geerinck A, Mkinsi O, Charles A, Rizzoli R, Cooper C, Avouac B, Bruyère O. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019 Apr;36(Suppl 1):65-99.
12. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, Callahan L, Copenhaver C, Dodge C, Felson D, Gellar K, Harvey WF, Hawker G, Herzig E, Kwoh CK, Nelson AE, Samuels J, Scanzello C, White D, Wise B, Altman RD, DiRenzo D, Fontanarosa J, Giradi G, Ishimori M, Misra D, Shah AA, Shmagel AK, Thoma LM, Turgunbaev M, Turner AS, Reston J. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020 Feb;72(2):149-162.
13. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M, Blanco FJ, Espinosa R, Haugen IK, Lin J, Mandl LA, Moilanen E, Nakamura N, Snyder-Mackler L, Trojian T, Underwood M, McAlindon TE. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov;27(11):1578-1589.